Dr. Fernando Ribeiro

Biography

Hospital Assistant in Urology, Specialist in Urology and Fellow of the European Board of Urology. Clinical practice at Hospital Prof. Dr. Fernando Fonseca (HFF).

Publications

Selected publications from PubMed

Cognitive Impairment in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review.

Barreira JV, Barreira P, Falcão G, Garcez D, Silva P, Santos G, Fontes-Sousa M, Leão Mendes J, Reis F, Santos CF, Ribeiro F, Capelas ML

Cancers (Basel). 2025 Jul 29;17(15) doi: 10.3390/cancers17152501.

Urothelial Carcinoma on a Ureterocele: Case Report and Review of the Literature.

Pinheiro AM, Galante Pereira F, Bargão P, Germano A, Ribeiro F

Cureus. 2023 Dec;15(12):e50549 doi: 10.7759/cureus.50549.

Prevalence of left renal vein compression (nutcracker phenomenon) signs on computed tomography angiography of healthy individuals.

Ribeiro FS, Puech-Leão P, Zerati AE, Nahas WC, David-Neto E, De Luccia N

J Vasc Surg Venous Lymphat Disord. 2020 Nov;8(6):1058-1065 doi: 10.1016/j.jvsv.2020.04.005.

Impact of positive surgical margins on biochemical relapse after radical retropubic prostatectomy (RRP).

Santos PB, Graça B, Lourenço M, Coelho MF, Ribeiro F, Fonseca J, Cardoso AP, Varregoso J, Ferrito F, Gomes FC

Cent European J Urol. 2011;64(4):223-8 doi: 10.5173/ceju.2011.04.art7.

Featured in

12 min

5 things you should know about Penile Cancer

Penile cancer is an uncommon tumor, with an incident of 1/100,000 in developed countries. There are many associated risk factors, such as phimosis, chronic penile inflammation, HPV, smoking, among others. The only protective factor is neonatal circumcision. HPV is associated with 1/3 of invasive penile cancer. Squamous cell carcinoma is the most common histological subtype. 80% of penile cancer is curable if diagnosed early. However, there is significant delay in seeking health care, with some patients coming with more than 1 year’s delay. Physical examination of the penile lesion and groin for inguinal lymph node disease is vital for diagnostic evaluation and future patient management. Penile ultrasound and MRI are valid options to stage corporal invasion and CT or PET/CT to stage lymph node involvement when indicated. Local treatment is the treatment to the primary lesion and its recurrence does not significantly influence long-term survival. Therefore, if possible, penile preservation treatments should be offered. There are many options to achieve better cosmetic and functional outcomes, depending on the degree of invasiveness. The number and the extent of lymph node involvement is the main prognostic factor, and thus correct staging and treatment is mandatory. When nodes are not palpable, staging surgery might be needed. When nodes are palpable, radical inguinal lymphadenectomy is indicated. It is associated with relevant morbidity; however, the fear of complications should not delay a potentially life-saving surgery. Penile cancer treatment has a significant negative impact on quality of life and sexual function. Penile sparing treatment seems to have better results than more invasive options.

Published

Nov 2021

15 min

New Options in BCG Unresponsive Bladder Cancer

Non-muscle invasive bladder cancer (NMIBC) represents 75% of bladder cancer. It commonly recurs and may progress to muscle invasive (MIBC). BCG immunotherapy is an adjuvant treatment recommended in intermediate and high-risk NMIBC. Treatment failure with intravesical BCG immunotherapy is defined as any high-grade recurrence during or after BCG treatment. BCG-unresponsive is defined as all BCG-refractory (recurrence during BCG treatment) and some BCG-relapsing (recurrence after completion of treatment) papillary recurrence after 6 months and for Cis recurrence after 12 months. BCG-unresponsive bladder cancer is unlikely to respond to further BCG treatment: therefore BCG is not useful. Radical cystectomy is the standard and preferred treatment option; however, it is associated with significant morbidity and mortality. Therefore, many patients are unwilling or unable to undergo the procedure. Until 2020, valrubicin was the only drug approved by the FDA, with disappointing results on its trial. Pembrolizumab was approved by the FDA in 2020 based on KEYNOTE 057 results, making it the second drug approved in this setting. Many other treatments, such as sequential intravesical gemcitabine and docetaxel instillations, hyperthermic intravesical chemotherapy, radiofrequency-induced thermo-chemotherapy effect (RITE), intravesical nadofaragene firadenovec gene therapy, oportuzumab monatox have been studied on this setting. These last two treatments are the most promising and are awaiting FDA review for approval.